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Abstract
Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and cytopenias 
due to uncontrolled programmed cell death. The presence of pro-inflammatory cytokines and 
constitutive activation of innate immunity signals in MDS cells suggest inflammatory cell death, 
such as necroptosis, may be responsible for disease phenotype. We evaluated 64 bone marrow 
samples from 55 patients with MDS or chronic myelomonocytic leukemia (CMML) obtained prior 
to (n=46) or after (n=18) therapy with hypomethylating agents (HMAs). RNA from sorted bone 
marrow CD34+ cells was isolated and subject to amplification and RNA-Seq. Compared to 
healthy controls, expression levels of MLKL (CMML: 2.09 log2FC, p=0.0013; MDS: 1.89 
log2FC, p=0.003), but not RIPK1 or RIPK3, were significantly upregulated. Higher expression 
levels of MLKL were associated with lower hemoglobin levels at diagnosis (−0.19 log2FC per 
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1g/dL increase of Hgb, p=0.03). Significant reduction in MLKL levels was observed after HMA 
therapy (−1.06 log2FC, p=0.05) particularly among non-responders (−2.89 log2FC, p=0.06). 
Higher RIPK1 expression was associated with shorter survival (HR 1.92, 95% CI 1.00–3.67, 
p=0.049 by Cox proportional hazards). This data provides further support for a role of necroptosis 
in MDS, and potentially response to HMAs and prognosis. This data also indicates that RIPK1/
RIPK3/MLKL are potential therapeutic targets in MDS.
Keywords
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INTRODUCTION
Myelodysplastic syndromes (MDS) are a heterogenous group of disorders characterized by 
ineffective hematopoiesis leading to cytopenias and a variable risk of progression and 
transformation to acute myeloid leukemia (AML) (1, 2). Although the mechanisms leading 
to ineffective hematopoiesis have not been fully elucidated, differentiation block and 
programmed cell death are known contributors to this phenomenon (3). Studies evaluating 
the role of apoptosis and the expression of apoptosis regulatory genes in MDS (4–8) have 
led to inconsistent results, with reported rates of apoptosis ranging from 2.5 to 56.3% and 
caspase 3, caspase 8, and annexin V positivity in bone marrow CD34+ cells varying in 
different studies based on morphologic and prognostic disease subgroups. Overexpression of 
Fas and Fas-Ligand have been reported in bone marrow CD34+ MDS cells (4), but 
activation of these receptors could also lead to necrotic cell death (9), and not only 
apoptosis. In addition, programmed cell death in MDS CD34+ cells has been shown to be 
upregulated and modulated by Toll-like receptors (TLRs) (8, 10). Innate immunity signaling 
mediated through TLRs, inflammatory cytokines (i.e., IL-1, IL-6, and IL-8), and damage 
associated molecular patterns (DAMPs) such as S100A8/9 are observed among most MDS 
subtypes (10, 11). This inflammatory background, the unclear role of apoptosis in MDS 
pathogenesis, and the high levels of tumor necrosis factor (TNF) in MDS (12–14), suggests 
alternative and less immune-silent mechanisms of cell death may be responsible for the 
disease phenotype. Although recent studies have described NLRP3-inflammasome mediated 
pyroptosis as a mediator of the MDS phenotype (15, 16), there are limited data evaluating 
the potential role of other inflammatory mechanisms of cell death in MDS pathogenesis. 
Recent studies suggest evasion of apoptosis through BCL2 upregulation may be involved in 
disease progression (17, 18). Whether this is the case with other forms of programmed cell 
death is unknown.
Necroptosis is a form of regulated necrotic cell death that can be activated under apoptosis-
deficient conditions and triggered by activation of death receptors (DRs) such as TNF 
receptor 1 (TNFR1) (9). Under specific conditions, activation of TNFR1 leads to activation 
of receptor-interacting protein kinase 1 (RIPK1) which phosphorylates and activates RIPK3 
to form a RIPK1-RIPK3-mixeld lineage kinase domain-like protein (MLKL) complex 
responsible for inducing cell death through membrane pore formation. Although necroptosis 
has been associated with multiple inflammatory conditions (9, 19), its potential role in MDS 
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remains unclear. A recent study by Wagner, et al evaluated a Vav-Cre-Bax/Bak/Bid triple 
knock out mouse model and demonstrated that unrestrained bone marrow necroptosis 
promoted inflammatory cytokine production that impaired hematopoietic stem-cell (HSPC) 
function. RIPK1 has also been shown to regulate hematopoiesis (20–22), mediate 
inflammation (9, 22), maintain chromosomal stability (23, 24), and modulate the expression 
of immune checkpoint molecules such as PD-1 or PD-L1 (23), which are known to be 
upregulated in MDS after failure to hypomethylating agent (HMA) therapy (25). In addition, 
inhibition of RIPK1 has been hypothesized as a potential therapeutic mechanism in several 
malignancies (26, 27).
In this study, we use RNA sequencing to analyze the expression level of the necroptosis 
complex components RIPK1, RIPK3, and MLKL in a total of 55 patients with MDS or 
chronic myelomonocytic leukemia (CMML), and to correlate this with response to HMA 
therapy and expression of apoptosis regulatory proteins and immune checkpoint regulators. 
We observed that MLKL was upregulated in MDS and CMML, and its downregulation was 
associated with absence of response to HMAs. In addition, we observed an association 
between necroptosome components and the BCL2 family of proteins and immune 
checkpoint regulators. Finally, we identified that RIPK1 expression levels predict prognosis 
of patients with MDS and were associated with innate immunity and pro-inflammatory 
signaling in MDS bone marrow CD34+ cells.
MATERIALS AND METHODS
Patients and Samples
We evaluated 64 bone marrow aspirates from 55 patients with MDS (n=34) or CMML 
(n=21) treated at the University of Texas MD Anderson Cancer Center (MDACC). Samples 
were obtained prior to (n=46) or after (n=18) HMA therapy. BM samples from healthy 
individuals were obtained from AllCells (Emeryville, CA). Patient characteristics are 
detailed in Supplemental Table S1. Informed consent was obtained according to protocols 
approved by the MDACC institutional review board in accordance with the Declaration of 
Helsinki. Diagnosis was confirmed in the hematopathology laboratory at MDACC by BM 
evaluation using 2016 WHO criteria. Conventional karyotyping was performed on fresh BM 
aspirates using standard procedures and reported following ISCN 2013 Nomenclature. 
Patients were classified using the revised 2016 WHO classification (28). Prognostic risk was 
calculated using both the International Prognostic Scoring System (IPSS) (2) and the revised 
IPSS (1). Response assessment was performed following the IWG 2006 criteria (29). On 
selected cases, immunohistochemical staining was performed on 4 μm thick formalin fixed 
paraffin embedded BM sections using standard procedures as described elsewhere using a 
mouse monoclonal antibody for BCL2 oncoprotein (Bcl-2/100/D5; 1:50, Leica(30)).
Isolation of BM CD34+ cells
MDS and CMML bone marrow (BM) aspirates were freshly obtained from patients referred 
to the Department of Leukemia at MDACC under approved protocols (LAB01–473). BM 
samples from healthy individuals were obtained from AllCells (Emeryville, CA). CD34+ 
cells were isolated using the CD34 MicroBead Kit (Miltenyi Biotec, Canada).
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RNA from sorted BM CD34+ cells was isolated using the PicoPure RNA isolation kit 
(Fisher Scientific, Waltham, MA) before RNA amplification and RNA-Seq library 
construction. Fastq files were mapped to the human genome (build GRCh38) in TopHat2 
using the default options (31). Differential gene expression analysis was conducted using 
DESeq2 in R version 3.4.2 (32). Gene expression was normalized for plotting using the 
variance-stabilizing transformation implemented in the DESeq2 package. Gene co-
expression was evaluated using Spearman correlation for the full data set, and using the 
Pearson correlation for analyses within subsets (due to small sample sizes). Pathway 
enrichment analysis was performed using gene set enrichment analysis, with the fgsea 
library in R (33). Genes were ranked according to their Spearman correlation with the gene 
of interest, and this ranking was used as the input to fgsea. 10 000 gene permutations were 
used to calculate statistical significance, and a false discovery corrected p-value of 0.05 was 
required for statistical significance of a gene set.
Targeted Gene Sequencing
Genomic DNA was extracted from whole bone marrow samples and subject to amplicon-
based targeted next-generation sequencing (NGS) evaluating a panel of 81 genes. This 
analysis was performed within our CLIA-compliant molecular diagnostics laboratory after 
informed consent (additional details in Supplemental Methods). A total of 250 ng of 
genomic DNA extracted from whole mononuclear cells from fresh BM aspirate was used for 
library preparation using HaloPlex chemistry (Agilent Technologies, Santa Clara, CA). 
Multiplexed bi-directional sequencing was performed on a MiSeq V3 300 cycle kit 
(Illumina, SanDiego, CA) using appropriate controls (310 cycles). Sequencing data was 
processed through MiSeq reporter (Illumina) and SureCall 3.0 (Agilent) with GRCh37/hg19 
as a reference for sequence alignment. For variant calling, a minimum coverage of 250x in 
both directions and a minimum of 2% allelic frequency were required. For confirmation, all 
variant calls were visualized using Integrative Genomics Viewer (34). Since matched 
germline controls were not sequenced, the somatic nature of the variants was determined 
using a combination of parameters. These included variant allele frequencies and available 
data in the literature and COSMIC. Single nucleotide polymorphisms (SNPs) reported in the 
Exome Aggregation Consortium (ExAC), dbSNP 137/138, and 1 000 Genomes Project were 
excluded. FLT3 mutational analysis for internal tandem duplication was also performed by 
PCR and capillary electrophoresis.
RESULTS
MLKL is overexpressed in MDS and CMML irrespective of WHO category or genomic 
context, and is associated with anemia severity
We compared RIPK1, RIPK3, and MLKL expression levels in patients with MDS and 
CMML at the time of diagnosis. Compared to healthy controls, MLKL (CMML vs controls: 
2.09 log2FC, p=0.0013; MDS vs control: 1.89 log2FC, p=0.003), but not RIPK1 or RIPK3, 
were significantly upregulated in patients with MDS and CMML (Figure 1). A trend of 
higher MLKL and RIPK3 levels was observed in patients with MDS and multilineage 
dysplasia (n=2) compared to other MDS subtypes. Targeted sequencing was available at the 
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time of diagnosis in 16 patients with MDS and 13 with CMML (Figure S1). We correlated 
expression levels of MLKL, RIPK1, and RIPK3 with detected mutations. To minimize the 
risk of biased associations due to small numbers, only mutations observed in at least 3 
patients were considered. No differences in the level of expression of RIPK1, MLKL or 
RIPK3 were observed based on the mutation context or burden. Since RIPK1 is known to 
participate in chromosomal stability, we correlated its expression levels with presence of 
cytogenetic abnormalities. No significant difference in RIPK1, RIPK3 or MLKL expression 
levels was observed based on presence of cytogenetic abnormalities (RIPK1: 0.10 log2FC, 
p=0.6; RIPK3: −0.39 log2FC, p=0.40; MLKL: 0.34 log2FC, p=0.30). In order to determine 
whether higher expression levels of MLKL translated into worse ineffective hematopoiesis, 
we correlated MLKL expression with the number and degree of cytopenias. Higher 
expression levels of MLKL were associated with lower hemoglobin levels at the time of 
diagnosis (−0.19 log2FC per 1g/dL increase of Hgb, p=0.03) (Figure 1). Since MLKL-
mediated necroptosis is associated with cytokine release and a pro-inflammatory response, 
and given the association between MLKL expression and anemia, we evaluated the 
association between MLKL expression and cytokine signaling. MLKL expression was 
significantly correlated with cytokine signaling using Gene Set Enrichment Analysis (NES 
2.51, q=0.024) (Figures 1 and S2). We then associated levels of expression of receptors 
associated with induction of necroptosis. Compared to healthy controls, expression levels of 
TRAIL, but not TNFRSF1A, were significantly higher in patients with CMML and MDS 
(CMML vs control: 3.22 log2FC, p<0.001, q<0.001; MDS vs control: 2.59 log2FC, 
p<0.001, q<0.001).
MLKL is downregulated in bone marrow CD34+ cells from patients with MDS who do not 
achieve response to azacitidine or decitabine
In order to assess whether HMA treatment modified the expression profile of the necroptosis 
complex, we evaluated RIPK1, RIPK3, and MLKL levels after HMA therapy in patient 
matched and unmatched samples. Clinical characteristics of responders and non-responders 
are detailed in Supplemental Table S2. As observed prior to therapy, MLKL levels, but not 
RIKP1 and RIKP3, were significantly increased both in MDS and CMML compared to 
healthy controls (Figure S3). Exposure to HMA therapy was associated with a trend to 
decreased expression of MLKL (−0.52 log2FC, p=0.08) when all post-HMA therapy 
samples were evaluated. Among patient matched samples, a significant reduction in MLKL 
levels was observed after HMA therapy (−1.06 log2FC, p=0.05). The degree of reduction in 
expression levels was greater among non-responders (−2.89 log2FC, p=0.06) compared to 
patients who experienced a response to therapy (−0.78, log2FC, p=0.06). Progression to 
AML with expansion of the blast population was observed in the 2 non-responder patients 
with matched pre- and post-therapy samples.
RIPK1 and MLKL expression levels correlate with expression of the BCL2 family of 
proteins and PD-1 after exposure to HMAs
Because necroptosis can only occur in apoptosis-deficient conditions and is associated with 
immune regulation, we studied the correlation of RIPK1, RIPK3, and MLKL expression 
levels with those of the BCL2 family of proteins and immune checkpoint regulatory 
molecules PD-1, PD-L1, and CTLA4. Levels of RIPK3 were negatively correlated with 
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BAK and positively correlated with BID and BIM in responding patients prior to therapy 
(n=16) and strongly correlated with PD-1 and negatively correlated with BIM after therapy 
(n=7) (Figure 2). In addition, MLKL expression was strongly correlated with BCL2 
expression. Among non-responders, RIPK1 and RIPK3 expression was strongly correlated 
with PUMA and BAK prior to therapy (n=11) (Figure 2) with MLKL expression correlating 
with BID and PUMA levels, RIPK3 with PD-1 levels and RIPK1 with BAK after therapy 
(n=6). In addition, RIPK1 had a strong negative correlation with BAX levels.
In view of the overexpression of MLKL compared to healthy controls, the decrease in 
expression levels after HMA therapy, and their correlation with BCL2 expression, we 
evaluated BCL2 protein expression in blasts/immature cells by IHC in a subset (n=11) of 
patients before (n=8) and after therapy (n=3) with HMA (Table 1). Among pre-treatment 
samples from responders (n=4), MLKL was overexpressed in all compared to controls. No 
significant BCL2 protein expression could be observed in blasts/immature cells. In addition, 
BCL2 mRNA expression was decreased compared to controls in 3 patients. Among pre-
treatment samples from non-responders (n=4), BCL2 protein detection by IHC was strongly 
positive in 2 patients coinciding with high BCL2 RNA expression, and negative in 2 patients 
with decreased BCL2 RNA expression. MLKL was overexpressed compared to controls in 
all 4 patients. Finally, post-treatment samples from non-responders (n=3) revealed BCL2 
IHC positivity in all patients, along with downregulation of MLKL and upregulation of 
BCL2 in 2 patients. Examples of positive and negative BCL2 IHC are shown in 
Supplemental Figure S4.
RIPK1 levels are associated with adverse prognosis and distinct gene pathway enrichment
We next evaluated the impact of RIPK1, RIPK3, and MLKL expression levels on prognosis 
of patients with MDS and CMML. Expression levels of RIPK1 at the time of diagnosis 
predicted for shorter survival for patients with high RIPK1 levels, defined as a log 
expression higher than median mRNA expression values, having significantly shorter overall 
survival compared to those with lower expression levels (median OS 10.7 vs 24.2 months, 
HR 1.92, 95% CI 1.00–3.67, p=0.049 by Cox proportional hazards) (Figure 3). This survival 
difference was even more notable when evaluating MDS patients only (median OS 10.5 
months vs 24.2 months, HR 7.09, 95% CI 2.06–24.3, p=0.002 by Cox proportional hazards) 
(Figure 3). Although patients with higher RIPK1 levels showed a trend toward have higher 
bone marrow blast percentage, higher IPSS-R risk categories, and lower hemoglobin and 
platelets, these differences were not significant (Supplemental Figure S5). Distribution of 
WHO subtype, IPSS-R risk category, cytogenetics, and mutation profile based on RIPK1 
expression is shown in Figure 4. A multivariate analysis for overall survival using both 
IPSS-R risk and RIPK1 expression levels demonstrated that high RIPK1 expression was an 
independent adverse prognostic factor in MDS patients (HR 6.83, 95% CI 1.74–26.8, 
p=0.006).
To elucidate the potential mechanisms underlying this survival difference we evaluated 
differentially expressed genes in patients with high compared to low RIPK1 expression. A 
total of 359 genes were significantly correlated with RIPK1 levels in MDS CD34+ cells 
(Spearman’s method q<0.2, Supplemental Table S3). Among these, 21 genes were positively 
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correlated with RIPK1 expression, while 17 genes were negative correlated (Spearman’s 
correlation, q<0.1). Gene set enrichment analysis identified 373 gene sets that significantly 
correlated with RIPK1 expression (Supplemental Table S4). Upregulated genes were 
associated with molecular signals associated with innate immunity and inflammatory 
signaling including TNF-α signaling via NFκB, NFκB signaling, the IFN-γ pathway, and 
RIG-I-like receptor (RLRs) signaling genes (Figure 5). Genes found to be differentially 
downregulated were associated with ATP synthesis and respiratory electron transport, 
oxidative phosphorylation, APC/CDC20 mediated degradation of mitotic proteins, and E2F 
targets.
DISCUSSION
Increasing evidence supports the involvement of inflammatory forms of cell death, such as 
pyroptosis, in MDS pathogenesis (15). Although a recent study suggests the potential role of 
necroptosis in MDS pathophysiology (35), the implications of this inflammatory cell death 
in disease progression, response to therapy or prognosis are unknown. In this study, we 
performed RNA-Seq on isolated CD34+ bone marrow cells from patients with MDS and 
CMML, and observed overexpression of MLKL, the effector molecule of necroptosis, and 
determined its association with the severity of anemia and response to hypomethylating 
agents. In addition, we determined that necroptosome component expression may be 
associated with expression of the BCL2 family of proteins and immune checkpoint 
regulators and that RIPK1 expression levels were associated with worse than expected 
survival, as determined by IPSS-R, and enriched innate immunity and inflammatory 
signaling.
Ineffective hematopoiesis in MDS has been traditionally associated with impaired 
differentiation and apoptosis of hematopoietic stem and progenitor cells (HSPCs). Recent 
studies suggest the potential role of inflammatory forms of death in MDS. In a study by 
Basiorka, et al (16), NRLP3-inflammasome mediated pyroptosis was found to participate 
and be particularly enriched compared to apoptosis in patients with lower-risk MDS. More 
recently, Wagner, et al (35) reported bone marrow failure and myelodysplasia in a triple 
knock out (Vav-Cre Bax/Bak/Bid), apoptosis-resistant mouse model in which increased 
RIPK1 kinase activity mediated bone marrow necroptosis. Increased expression of RIPK1 
and pMLKL by immunofluorescence was also observed in bone marrow samples from 
patients with MDS, particularly among those with MDS with multilineage dysplasia (MDS-
MLD) compared to those with excess blasts (MDS-EB). This data suggests necroptosis may 
be responsible for early stages of the disease and that, as the disease progresses, additional 
genomic and epigenomic abnormalities may lead to evasion of cell death and clonal 
expansion. In our study, by evaluating necroptosome components at the transcriptomic level, 
we also identified overexpression of MLKL in MDS and a trend toward higher expression in 
patients with MDS-MLD. In addition, higher expression levels were associated with more 
severe anemia, which supports the notion that necroptosis may mediate ineffective 
erythropoiesis. Future studies confirming whether increased MLKL expression leads to 
impaired erythroid colony formation will be required. Also, although increased expression 
levels of RIPK1 at the time of diagnosis independently predicted for a worse overall 
survival, the underlying mechanism behind this remains unclear. Although Wagner et al 
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demonstrated that samples from patients with MDS-MLD and MDS with ring sideroblasts 
showed increased expression of RIPK1 compared to 50% of samples from patients with 
MDS-EB, we did not observe significant differences in RIPK1 expression based on MDS 
WHO subtype, blast percentage, IPSS or IPSS-R category. This may be related to small 
patient numbers (22 samples in the study by Wagner, et al and 64 in our study) or differences 
in the study populations, such as a higher proportion of MDS-EB in our study. Further 
confirmation of the degree of activity and transcription of RIPK1 will be needed. By 
evaluating necroptosome component expression after therapy with the HMAs azacitidine 
and decitabine, we observed significant downregulation of MLKL, particularly among non-
responding patients who also experienced progressive disease with blast expansion at the 
time of failure. This suggests that, during the process of emergence of resistance to HMAs, 
HSPCs may downregulate MLKL to evade necroptosis and have a survival advantage 
facilitating clonal expansion and disease progression. Similar functional changes leading to 
evasion of apoptosis have been described at the time of failure to HMA due to upregulation 
of BCL2 (17, 18). In our study, we observed a strong correlation between MLKL, BIM, and 
PUMA expression after therapy in non-responding patients, further suggesting that evasion 
of apoptosis and necroptosis may be involved in disease progression. By evaluating BCL2 
protein expression by IHC, we observed that only non-responding patients had detectable 
BCL2 protein in blasts and immature myeloid cells, particularly after therapy with HMA, 
and this was associated with corresponding upregulation of BCL2 at the RNA level along 
with downregulation of MLKL RNA compared to pre-treatment in 2 out of 3 patients. 
Future functional studies will be required to evaluate this relationship further and confirm 
whether downregulation of necroptosis along with upregulation of pro-survival BCL2 family 
of proteins may be responsible for disease progression.
Upregulation of innate immunity and pro-inflammatory signaling are involved in MDS 
pathogenesis (11, 36). Several studies have shown constitutive TLR signaling in MDS 
leading to upregulation of genes involved in NFκB signaling, IL-8 over-production, and 
inhibition of colony formation potential, particularly in CD34+ cells from patients with 
previous exposure to HMAs (10, 37). In our cohort, higher expression levels of RIPK1 were 
associated with significant overexpression of genes involved in TNF-α and NFκB signaling 
and RLRs, which mediate PAMP recognition, immune signaling, and production of IFN 
(38). In line with previous studies (22, 23), this data further supports the role of RIPK1 as a 
mediator of inflammation. Given that in our study, high RIPK1 expression was an 
independent adverse prognostic factor in patients with MDS and was associated with 
upregulation of innate immunity signaling, inhibition of RIPK1 alone or in combination with 
drugs targeting inflammation or innate immunity signaling might have a therapeutic role in 
MDS. In fact, we have previously reported the therapeutic potential associated with targeting 
innate immunity signaling in MDS by inhibition of JAK/STAT (39), TLR2 (40), p38 MAPK 
(41), or NFκB (40, 42). Moreover, consistent with previous studies linking RIPK1 function 
with PD-1 expression (23), we observed an association between RIPK3 and PD-1 expression 
levels. Given the preclinical data suggesting RIPK1 inhibition leads to upregulation of PD-1 
(23), the fact that overexpression of PD-1 may lead to ineffective hematopoiesis (43) and 
potentially to HMA failure (25) and the clinical activity of PD-1 inhibitors in MDS (44), this 
could support the concept of exploring dual RIPK1 and PD-1 inhibition in MDS.
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We acknowledge our study has several limitations. First, although mRNA expression is a 
valid way to assess the degree of activity of a given biological function, it is not an optimal 
tool to evaluate kinase activity and absence of phosphorylated protein evaluation limits our 
ability to confirm protein activation and degree of expression. In addition, the patient 
numbers included in our study are small and therefore limit the statistical power needed to 
generate robust associations. Third, only a subset of included samples corresponded to 
matched pre and post therapy samples, which this limits the ability to conclude whether the 
observed changes in expression are specific to therapy. Finally, functional studies will be 
required to confirm our findings and larger studies are necessary to evaluate the role and the 
prognostic significance of necroptosis in MDS and the functional link between evasion of 
necroptosis and disease progression.
Despite these limitations, our study is consistent with prior studies suggesting the potential 
role of necroptosis in MDS. In addition, to the best of our knowledge, this is the first study 
to associate expression of necroptosome components with loss of response and progression 
after HMA therapy in patients with MDS as well as prognosis, PD-1, and innate immunity 
expression. This sets the basis for future studies confirming these findings and evaluating 
RIPK1/RIPK3/MLKL as therapeutic targets for MDS alone or in combination with PD-1 
monoclonal antibodies or novel agents targeting innate immunity or inflammatory signaling.
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Figure 1. mRNA expression levels of necroptosome components in MDS and CMML and its 
association with cytopenias.
(A-C) Normalized log2 mRNA expression levels of RIPK1, RIPK3, and MLKL in bone 
marrow CD34+ cells from healthy controls, patients with myelodysplastic syndromes 
(MDS), or chronic myelomonocytic leukemia (CMML). Gene expression was normalized 
for plotting using the variance-stabilizing transformation implemented in the DESeq2 
package. (D) Correlation of normalized MLKL log2 mRNA expression levels with 
hemoglobin (g/dL). (E) Gene set enrichment analysis showing correlation between MLKL 
expression levels and cytokine signaling genes. Heatmap shows degree of correlation and 
log2 expression of each given gene.
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Figure 2. Association of necroptosome component expression levels with the BCL2 family of 
proteins and immune checkpoint regulators.
Graphs represent correlograms of RIPK1, RIPK3, and MLKL expression levels from bone 
marrow CD34+ cells with those of the BCL2 family of proteins and immune checkpoint 
regulatory molecules PD-1, PD-L1, and CTLA4. Only statistically significant associations 
(p<0.05) are represented. (A) Levels of RIPK3 were negatively correlated with BAK and 
positively correlated with BID and BIM in responding patients prior to therapy and strongly 
correlated with PD-1 and negatively correlated with BIM after therapy. In addition, MLKL 
expression was strongly correlated with BCL2 expression. (B) Among non-responders, 
RIPK1 and RIPK3 expression was strongly correlated with PUMA and BAK prior to 
therapy with MLKL expression correlating with BID and PUMA levels, RIPK3 with PD-1 
levels and RIPK1 with BAK after therapy. In addition, RIPK1 had a strong negative 
correlation with BAX levels.
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Figure 3. Impact of RIPK1 expression levels on survival of patients with MDS and CMML.
(A) Kaplan-Meier survival estimate curve for overall survival based on high (log2FC 
expression above median) versus low (log2FC expression below median) RIPK1 mRNA 
expression levels in bone marrow CD34+ cells from patients with MDS and CMML. (B) 
Kaplan-Meier survival estimate curve for overall survival based on high (log2FC expression 
above median) versus low (log2FC expression below median) RIPK1 mRNA expression 
levels in patients with MDS.
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Figure 4. Clinical and genomic features of MDS patients based on RIPK1 expression level.
Heat map details the WHO category, IPSS-R category, karyotype, and NGS mutational 
profiles of patients with MDS at the time of diagnosis. Patient population is clustered based 
on RIPK1 expression levels: high (mRNA expression levels >median mRNA expression 
levels) or low (mRNA expression levels <median mRNA expression levels). DNA meth: 
DNA methylation. TSG: tumor suppressor genes. Coh: cohesins.
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Figure 5. Genomic set enrichment analysis showing differentially regulated pathways in patients 
with high RIPK1 expression.
Differentially upregulated and downregulated genes and pathways based on gene set 
enrichment analysis of patients with high RIPK1 expression levels. Significantly enriched 
pathways (FDR-adjusted p<0.05) were ranked by normalized enrichment score, and the top 
pathways in both directions are presented. Upregulated genes are associated with innate 
immunity and inflammatory signaling including TNF-α signaling via NFκB, NFκB 
signaling, IFN-γ pathway, and RIG-I-like receptor signaling genes. Downregulated genes 
are associated with ATP synthesis and respiratory electron transport, oxidative 
phosphorylation, APC/CDC20 mediated degradation of mitotic proteins, and E2F targets.
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Table 1.
BCL2 protein expression by immunohistochemistry and its association with MLKL and BCL2 RNA 
expression levels in responders and non-responders.
Time point Responder BCL2 IHC MLKL log2FC 
expression




BCL2 compared to 
median
Pre-treatment Yes Negative 7.23 Up 10.06 Up
Pre-treatment Yes Negative 10.01 Up 5.47 Down
Pre-treatment Yes Negative 7.82 Up 8.20 Down
Pre-treatment Yes Negative 8.10 Up 8.56 Down
Pre-treatment No +++ 7.79 Up 10.22 Up
Pre-treatment No + subset 8.15 Up 9.39 Down
Pre-treatment No Negative 7.54 Up 9.00 Down
Pre-treatment No +++ 7.83 Up 10.16 Up
Post-treatment No + 7.95 Down 10.55 Up
Post-treatment No +++ 8.09 Up 9.51 Up
Post-treatment No + subset 7.91 Down 7.50 Down
IHC: immunohistochemistry
Note: Upregulation or downregulation of MLKL and BCL2 were determined by increased log2FC expression levels compared to median 
expression in controls for pre-treatment samples, and median expression in MDS patients at diagnosis for post-treatment samples. Degree of 
positivity was determined by intensity of expression and percentage of positive cells with a grading of + to +++.
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